AI Article Synopsis
- Plasmacytoid urothelial carcinoma is a rare and aggressive form of bladder cancer, presented in a 75-year-old woman who had retroperitoneal spread of the disease.
- After first-line chemotherapy with gemcitabine and cisplatin failed, a circulating tumor cell test identified a cell positive for programmed death-ligand 1, leading to second-line treatment with pembrolizumab.
- Ultimately, despite treatment, the cancer progressed with severe infiltration in the retroperitoneum, and the patient passed away, highlighting the aggressive nature of this cancer variant.
Article Abstract
Introduction: Plasmacytoid urothelial carcinoma is a rare and aggressive variant of bladder cancer.
Case Presentation: A 75-year-old woman presented with plasmacytoid urothelial carcinoma with retroperitoneal dissemination was treated with chemotherapy. After an unsuccessful first-line chemotherapy with gemcitabine and cisplatin, we assessed circulating tumor cells; one such cell was found to be positive for programmed death-ligand 1. The patient received second-line chemotherapy with pembrolizumab. However, the tumor extended to the retroperitoneal organs, and the patient eventually died. Autopsy revealed a widespread diffuse scirrhous infiltration of the carcinoma into the retroperitoneum. However, distant metastasis was not observed.
Conclusion: The evaluation of circulating tumor cells and autopsy revealed a disease state of progressive plasmacytoid urothelial carcinoma treated with pembrolizumab.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469833 | PMC |
| http://dx.doi.org/10.1002/iju5.12167 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!